Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Millennium Velcade launch

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Shipments of Millennium's proteasome inhibitor Velcade (bortezomib) begin the week of May 19 following accelerated approval May 13 for "treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy." Approval is based on Phase II data from the 202-patient SUMMIT trial and the 54-patient CREST study (1Pharmaceutical Approvals Monthly Feb. 1, p. 9)...
Advertisement

Related Content

Millennium Expects Velcade Accelerated Approval In ’03: Is Phase II Enough?

Topics

Advertisement
UsernamePublicRestriction

Register

PS002276

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel